Focused on therapies for rare genetic forms of obesity, the company develops and commercializes drugs targeting the melanocortin‑4 receptor (MC4R) pathway. Its lead product, setmelanotide (marketed as Imcivree), is approved for certain ultra‑rare obesity disorders, with additional clinical studies e...
1 member of Congress has disclosed 3 trades in Rhythm Pharmaceuticals Inc (RYTM), a Healthcare company. The buy/sell breakdown shows 1 purchase versus 2 sales, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-07-05 | Byron Donalds | sell | $1K – $15K |
| 2023-07-05 | Byron Donalds | sell | $1K – $15K |
| 2021-05-05 | Byron Donalds | buy | $1K – $15K |